In high-risk patients with Diabetes and Cardiovascular Disease PLATELETS AND RISKS ARE DIFFERENT
DURLAZA® to reduce the risk of heart attacks, strokes, or death in high-risk patients such as those with diabetes and cardiovascular disease
Patients with diabetes suffer from the highest rate of CVD EVENTS
Data from the REACH registry, an international prospective cohort, illustrating the cumulative incidence of cardiovascular death, MI, or CVA over a 4-year period in patients with and without DM2 CVA= cerebrovascular accident.3
Cardiovascular Disease IN PATIENTS WITH DIABETES Creates a Highly Thrombotic Disease State
In high risk patients, platelet production and turnover may be increased due to several factors:
- Diabetes mellitus
- Elevated BMI
- Coronary Artery Disease
Immature platelets are more hyperactive, resulting in:
- Increased platelet adhesion
- Increased platelet sensitivity and activation
- Increased blood clotting
PATIENTS WITH CVD AND DIABETES produce a substantial number of platelets after regular aspirin is cleared from the blood
Regular aspirin leaves a substantial window of platelet production without aspirin in the bloodstream. Platelets under regular aspirin treatment are left unexposed for up to 20 hours,11,12 potentially leaving up to 80 billion newly formed platelets without aspirin exposure for 75% of the dosing interval.
DURLAZA, A PROVEN ER TECHNOLOGY formulation that provides 24-hour aspirin release.
Characteristic diffusion-based dissolution profile based on Fick's second law.
Platelet Inhibition in Patients with DIABETES MELLITUS AND CVD
Platelet Aggregation (blood clotting) assessed by LTA, Multiplatelet Analyzer© and VerifyNow© Aspirin Assay. Blood clotting was assessed after days 10-14 of treatment.15
Most patients can fill a DURLAZA prescription WITH LITTLE OUT-OF-POCKET COSTS
Click on picture to download your $0 Co-pay Card